Free Trial
CVE:KNE

Kane Biotech (KNE) Stock Price, News & Analysis

Kane Biotech logo
C$0.06 +0.01 (+9.09%)
As of 06/12/2025 02:35 PM Eastern

About Kane Biotech Stock (CVE:KNE)

Key Stats

Today's Range
C$0.06
C$0.06
50-Day Range
C$0.05
C$0.10
52-Week Range
C$0.05
C$0.17
Volume
200,000 shs
Average Volume
73,208 shs
Market Capitalization
C$8.64 million
P/E Ratio
1.50
Dividend Yield
3.08%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Receive KNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kane Biotech and its competitors with MarketBeat's FREE daily newsletter.

KNE Stock News Headlines

Kane Biotech (CVE:KNE) Shares Down 23.1% - What's Next?
Gold is soaring. Here’s how to get paid from it
Gold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.
Kane Biotech (CVE:KNE) Stock Price Down 23.1% - Here's Why
Kane Biotech (CVE:KNE) Trading Down 23.1% - Should You Sell?
Kane Biotech (CVE:KNE) Trading Down 23.1% - Time to Sell?
Kane Biotech (CVE:KNE) Trading Down 23.1% - What's Next?
See More Headlines

KNE Stock Analysis - Frequently Asked Questions

Kane Biotech's stock was trading at C$0.11 at the start of the year. Since then, KNE shares have decreased by 45.5% and is now trading at C$0.06.
View the best growth stocks for 2025 here
.

Shares of KNE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kane Biotech investors own include Mason Resources (LLG), Datametrex AI (DM) and Allstar Health Brands (ALST).

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
CVE:KNE
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
1.50
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$6.03 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$1.42 million
Cash Flow
C$0.01 per share
Price / Cash Flow
8.50
Book Value
C($0.01) per share
Price / Book
-11.66

Miscellaneous

Free Float
N/A
Market Cap
C$8.64 million
Optionable
Not Optionable
Beta
0.52
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (CVE:KNE) was last updated on 6/13/2025 by MarketBeat.com Staff
From Our Partners